CDC Morbidity & Mortality Weekly Report: Effectiveness of Monovalent mRNA Vaccines Against COVID-19 - Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in U.S.
January 03, 2023
January 03, 2023
ATLANTA, Georgia, Jan. 3 (TNSrep) -- The U.S. Department of Health and Human Services Centers for Disease Control and Prevention issued the following article entitled "Effectiveness of Monovalent mRNA Vaccines Against COVID-19 - Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, Dec.26, 2021-Aug. 31, 2022" as part of its Morbidity and Mortality Weekly Rep . . .